{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Aggressive+Behavior&page=12", "query": { "condition": "Aggressive Behavior", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 468, "total_pages": 47, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Aggressive+Behavior&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Aggressive+Behavior&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-05T14:32:15.725Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03575351", "title": "A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Standard of Care", "type": "DRUG" }, { "name": "JCAR017", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "GENETIC" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 184, "start_date": "2018-10-23", "completion_date": "2023-10-23", "has_results": true, "last_update_posted_date": "2025-08-03", "last_synced_at": "2026-11-05T14:32:15.725Z", "location_count": 28, "location_summary": "Scottsdale, Arizona • San Francisco, California • Aurora, Colorado + 22 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03575351" }, { "nct_id": "NCT02620254", "title": "Mast Cell Connect: A Registry for Patients With Mastocytosis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Mastocytosis" ], "interventions": [], "intervention_types": [], "sponsor": "Blueprint Medicines Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 743, "start_date": "2015-11", "completion_date": "2021-01", "has_results": false, "last_update_posted_date": "2021-02-04", "last_synced_at": "2026-11-05T14:32:15.725Z", "location_count": 1, "location_summary": "Cambridge, Massachusetts", "locations": [ { "city": "Cambridge", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02620254" }, { "nct_id": "NCT01458366", "title": "Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Ofatumumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "CT Scan", "type": "PROCEDURE" }, { "name": "PET Scan", "type": "PROCEDURE" }, { "name": "Stem Cell Transplant (STC)", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "PROCEDURE", "GENETIC" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2011-11-09", "completion_date": "2020-07-23", "has_results": true, "last_update_posted_date": "2025-04-30", "last_synced_at": "2026-11-05T14:32:15.725Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01458366" }, { "nct_id": "NCT01766336", "title": "A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "Group 1 ELND005", "type": "DRUG" }, { "name": "Group 2 ELND005", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OPKO Health, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "50 Years to 95 Years" }, "enrollment_count": 296, "start_date": "2013-01", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2019-10-21", "last_synced_at": "2026-11-05T14:32:15.725Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Encino, California + 35 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Encino", "state": "California" }, { "city": "Escondido", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01766336" }, { "nct_id": "NCT00088530", "title": "BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "pixantrone, cyclophosphamide, vincristine, rituximab, prednisone", "type": "DRUG" }, { "name": "Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CTI BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2004-07", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2020-02-05", "last_synced_at": "2026-11-05T14:32:15.725Z", "location_count": 9, "location_summary": "Fountain Valley, California • Los Angeles, California • Lakeland, Florida + 6 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Lakeland", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT00088530" }, { "nct_id": "NCT00782067", "title": "Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Midostaurin (PKC412)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2008-10-13", "completion_date": "2017-08-24", "has_results": true, "last_update_posted_date": "2018-11-15", "last_synced_at": "2026-11-05T14:32:15.725Z", "location_count": 9, "location_summary": "Los Angeles, California • Stanford, California • Augusta, Georgia + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00782067" }, { "nct_id": "NCT00538187", "title": "Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Non-Hodgkin Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "obatoclax mesylate", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2007-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-12-04", "last_synced_at": "2026-11-05T14:32:15.725Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00538187" }, { "nct_id": "NCT02290951", "title": "Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin Lymphoma", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Odronextamab multiple dose levels", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2015-01-09", "completion_date": "2025-08-21", "has_results": false, "last_update_posted_date": "2025-10-10", "last_synced_at": "2026-11-05T14:32:15.725Z", "location_count": 10, "location_summary": "Orange, California • Stanford, California • Tampa, Florida + 4 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02290951" }, { "nct_id": "NCT05362773", "title": "A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Acute Myeloid", "Myelodysplastic Syndromes", "Classical Hodgkin Lymphoma", "Leukemia, B-cell", "Leukemia, Hairy Cell", "Mastocytosis, Aggressive Systemic", "Blastic Plasmacytoid Dendritic Cell Neoplasm", "Chronic Myeloid Leukemia" ], "interventions": [ { "name": "MGD024", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2022-07-13", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-11-05T14:32:15.725Z", "location_count": 7, "location_summary": "Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 4 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05362773" }, { "nct_id": "NCT06118580", "title": "Neural Correlates During Alcohol Intoxication", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alcohol Use Disorder", "Intermittent Explosive Disorder" ], "interventions": [ { "name": "Alcohol (Ethanol)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "21 Years to 55 Years" }, "enrollment_count": 144, "start_date": "2023-06-08", "completion_date": "2026-08-31", "has_results": false, "last_update_posted_date": "2025-03-27", "last_synced_at": "2026-11-05T14:32:15.725Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06118580" } ] }